Molecular targets for healing or treating wounds
AssigneeUniversity College Cardiff Consultants Limited
InventorsWenguo Jiang, Keith Harding
Life of this patent
Estimating the term…
Abstract
The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is PTPRK, or a protein 50% homologous therewith, and which retains the same activity as PTPRK protein. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds.
Claims20
A therapeutic comprising an inhibitor of one or both of PTPRK gene expression or PTPRK protein activity or an inhibitor of a protein that is at least 50% homologous to PTPRK for use in the treatment of wounds.
A method for treating a mammalian wound which method comprises:
- administering to said wound a therapeutic that inhibits one or both of PTPRK gene expression or PTPRK protein activity.
A combination therapeutic for treating a wound comprising an inhibitor of PTPRK gene expression and an inhibitor of PTPRK protein activity.
A combination therapeutic for treating a wound comprising:
- a) either an inhibitor of PTPRK gene expression or an inhibitor of PTPRK protein activity;
- and
- b) at least one further therapeutic.
(canceled)
Dependencies are inferred from the claim text.